STAR-0602 is under clinical development by Marengo Therapeutics and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STAR-0602’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STAR-0602 overview
STAR-0602 is under development for the treatment of hematological malignancies, solid tumors, triple negative breast cancer, epithelial ovarian cancer, metastatic castration-resistance prostate cancer, merkel cell carcinoma, cervical cancer, oropharyngeal cancer, anal cancer, penile cancer, vaginal cancer, vulvar cancer, metastatic colorectal cancer and non-small cell lung cancer. The drug candidate is developed based on universal targeted immunotherapy (UniTI) platform and STAR (Selective T Cell Activation Repertoire) platform. The drug candidate is administered through intravenous route. The drug candidate selectively targets a common Vβ T cell subset
It was under development for the treatment of hematological tumor.
Marengo Therapeutics overview
Marengo Therapeutics, Inc (Marengo) is a clinical-stage biotech company that primarily focuses on the development of novel TCR-targeting antibodies. The company designs antibodies to selectively modulate common and disease-specific T cell subsets of the germline TCR repertoire, aiming to provide lifelong protection against cancer and other diseases. The company’s pipeline products include STAR0602, STAR0603, STAR0501, STAR0502 and TRISTAR0701. Marengo’s medications are used to treat solid tumors, cold tumors and cancer. The company also offers Selective T Cell Activation Repertoire (STAR) platform and the TriSTAR platform to enhance the immune system’s ability to combat cancer. Marengo’s products are primarily used in the healthcare industry for the treatment of various types of cancers. Marengo is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of STAR-0602’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
